MetaCap

Neumora Therapeutics (NMRA) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OKYO Pharma (OKYO) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 49.5% versus a loss of 85.7%. Neumora Therapeutics is the larger company by market cap ($63.0 million vs $56.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NMRA-85.67%OKYO-49.53%
+61%-16%-93%
Nov 21, 20251 yearNov 20, 2026
NMRA-97.95%OKYO-46.23%
+72%-17%-106%
Sep 11, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NMRA versus OKYO key metrics
MetricNMRAOKYO
Share price$0.3339$1.07
Market cap$63.01M$56.15M
1-day change-3.78%-7.76%
YTD return-81.35%-48.31%
1-year return-85.67%-49.53%
EPS (TTM)$-1.06$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-236.93M$-4.71M
52-week high$3.65$3.20
52-week low$0.301$1.00
Distance from 52-week high-90.85%-66.56%
Analyst consensusbuystrong_buy
Avg. price target upside+1696.95%+678.50%
Average volume1.69M143.41K
Shares outstanding188.69M52.48M
Employees635
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKYO has outperformed NMRA by 36.1 percentage points over the past year.

About Neumora Therapeutics

NMRA stock →

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

NMRA vs OKYO FAQ

Which is bigger, Neumora Therapeutics or OKYO Pharma?

Neumora Therapeutics (NMRA) is larger, with a market capitalization of $63.01M compared with $56.15M for OKYO Pharma (OKYO).

Which stock has performed better over the past year, NMRA or OKYO?

OKYO returned -49.53% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.

Are Neumora Therapeutics and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons